Institut suisse de recherche expérimentale sur le cancer ‐ EPFL

L’intégration de la recherche fondamentale et translationnelle sur le cancer à la biologie fondamentale cellullaire et développementale.

Biologie cellulaire et moléculaire du développement et du cancer

Recherche fondamentale et translationnelle sur le cancer

Chaire Paternot en recherche interdisciplinaire sur le cancer

Histological staining of a lung adenocarcinoma, which is made of tumor cells as well as cells of the immune microenvironment including tumor-associated neutrophils. Credit: Caroline Contat (EPFL).

Lung cancer resistance: the key is glucose

Published:22.03.21 — Lung tumors are home to immune cells that affect their growth and resistance to treatment. Looking at neutrophils, scientists led by EPFL have discovered that the key might lie in the cells’ ability to metabolize glucose, opening an entirely new target for improving radiotherapy.

Invasive Lobular Carcinoma Intraductal Xenograft Tissue Section Stained for Fibrillar Collagen. Credit: George Sflomos (EPFL)

Scientists model a peculiar type of breast cancer

Published:24.02.21 — Scientists led by EPFL have developed a breakthrough in vivo model for invasive lobular carcinoma, a serious yet understudied type of breast cancer. The work will open up previously inaccessible study of the tumor’s biology and help discover new therapies.

A screenshot of MarrowQuant annotating a bone marrow trephine biopsy from a patient surfing from chemotherapy-induced aplasia. Credit: Olaia Naveiras (EPFL)

MarrowQuant: a digital-pathology tool

Published:29.09.20 — EPFL scientists have developed a digital pathology workflow for quantifying bone marrow compartments in standard histological sections. Named “MarrowQuant”, this workflow based on the open source software QuPath makes it possible to examine bone marrow biopsies as well as to re-examine historical collections of bone-marrow samples and even old clinical trials.

Toutes les actualités